Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics
E coli
Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics. Complicated urinary tract infections (cUTI), in particular, constitute a massive health burden on patients, affecting more than 100 million people per year globally.
Contagion® previously reported on results from the phase 3 ALLIUM clinical trial of Allecra Therapeutics’ investigational antibiotic combination of cefepime-enmetazobactam (FPE), and now the research team presents additional findings during the virtual ID Week 2020.
FPE fuses enmetazobactam, a novel ESBL inhibitor, with cefepime, a fourth-generation cephalosporin, to target infections, specifically cUTI and acute pyelonephritis (AP), caused by ESBL-producing Enterobacterales.
In the ALLIUM trial, FPE demonstrated superiority to piperacillin-tazobactam (PTZ) in a subgroup of patients with ESBL-producing baseline uropathogens (ESBL-BU).
“We anticipated excellent activity of this antibiotic,” investigator Keith Kaye, MD, of the University of Michigan Medical School, told Contagion® earlier this year. “The fact that it was superior to piperacillin-tazobactam and its notable efficacy in cUTIs due to ESBL-producers I found to be very exciting.”
For this double-blind, multicenter trial, a total of 1034 participants with either cUTI or AP were randomized 1:1 to receive either 2 g cefepime/0.5 g enmetazobactam or 4 g piperacillin/0.5 g tazobactam. Each treatment arm received the study drug combination every 8 hours via a 2-hour infusion for 7 to 14 days. For the primary analysis, success was defined as a combination of clinical cure and microbiological eradication in the microbiological modified intent-to-treat population (mMITT) at test-of-cure (TOC).
Investigators also performed subgroup analyses on patients with ESBL-BU non-resistant to FPE (MIC≤8 µg/ml) and PTZ (MIC≤64 µg/ml), as well as on patients with ESBL-BU resistant to either agent (FPE MIC ≥16 µg/ml or PTZ MIC≥128 µg/ml).
FPE demonstrated superiority to PTZ, with success observed in 273 of 345 (79.1%) patients, compared with 196 of 333 (58.9%) at TOC (difference, 21.2%; 95% CI: 14.3, 27.9).
According to the results, the prevalence rate of ESBL-BU in the first subgroup was 20.9% (142/678), with 99.3% (141/142) expressing a CTX-M-type (-1, -3, -9, -14, -15, -27, -55, -91, -169) and 3.5% (5/142) co-expressing AmpC (CMY-2/-59). In this group, FPE (56/76, 73.7%) was superior to PTZ (34/66, 51.5%) at TOC (difference 30.2%; 95% CI: 13.4, 45.1).
In the other subgroup, the “ESBL-BU prevalence rate was 22.3% (172/771), with 6.4% (11/172) co-expressing AmpC (CMY-2/-4/-59/-99), 4.7% (8/172) co-expressing a metallo-β-lactamase (VIM-1, NDM-1), and 2.3% (4/172) co-expressing OXA-48,” the study reads. In those patients, FPE superiority (67/91, 73.6%) was also observed when compared with PTZ (41/81, 50.6%) at TOC (difference 30.0%; 95% CI: 14.9, 43.3).
“Cefepime-enmetazobactam was very effective in treating cUTI, including against ESBL-producers. It also was safe and well-tolerated,” Kaye said. “Cefepime-enmetazobactam is a viable treatment option for cUTI due to gram-negative bacilli and is intended to be a carbapenem-sparing option for those that are ESBL-producers.”
The study, “Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales,” was presented virtually at ID Week 2020.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.